Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Immunotherapy based on dendritic cells: from experimentation to clinical development].

M Goldman1

  • 1Laboratoire d'immunologie expérimentale ULB, Bâtiment G/E, 808, route de Lennik CP 615, 1070, Bruxelles, Belgique. mgoldman@ulb.ac.be <mgoldman@ulb.ac.be>

Pathologie-Biologie
|June 13, 2003
PubMed
Summary

Researchers explored dendritic cell (DC) immunotherapy for cancer, focusing on generating novel human dendritic cells and enhancing their anti-cancer potential for clinical applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endogenous IL-10 protects mice from death during septic peritonitis.

Journal of immunology (Baltimore, Md. : 1950)·1995
Same author

Effects of prenatal ultrasound exposure on adult offspring behavior in the Wistar rat.

Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)·1995
Same author

Role of defective monocyte interleukin-10 release in tumor necrosis factor-alpha overproduction in alcoholics cirrhosis.

Hepatology (Baltimore, Md.)·1995
Same author

Differential effect of human immunodeficiency virus infection on the IgA and IgG antibody responses to pneumococcal vaccine.

The Journal of infectious diseases·1995
Same author

Interleukin-5 production by T lymphocytes in atheroembolic disease with hypereosinophilia.

The Journal of allergy and clinical immunology·1995
Same author

Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells.

European journal of immunology·1995

Area of Science:

  • Immunotherapy
  • Cellular immunology
  • Cancer research

Context:

  • Dendritic cell (DC)-based cancer immunotherapy shows promise in preclinical studies.
  • Translating DC immunotherapy to human applications requires addressing challenges in DC generation, functional analysis, and patient immunomonitoring.
  • Current research focuses on optimizing DC potential for clinical use.

Purpose:

  • To investigate the cytotoxic activity of dendritic cells.
  • To generate a novel population of human dendritic cells from monocytes using Interleukin-3 (IL-3) and Interferon-beta (IFN-beta).
  • To enhance the immunostimulatory properties of dendritic cells through Fas-ligand overexpression or adjuvants that promote DC/gamma-delta T cell interactions.

Summary:

  • This study focuses on key aspects of dendritic cell (DC) immunotherapy for cancer.

Related Experiment Videos

  • It details the investigation into DC cytotoxic activity.
  • A novel method for generating human dendritic cells from monocytes using IL-3 and IFN-beta is presented, alongside strategies to optimize their immunostimulatory functions, including Fas-ligand overexpression and adjuvants for enhanced DC/gamma-delta T cell interaction.

    • Impact:

    • Provides insights into optimizing dendritic cell generation and function for human cancer immunotherapy.
    • Contributes to the development of more effective DC-based cancer treatments.
    • Highlights strategies for improving DC immunogenicity and T cell engagement in cancer patients.